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Abstract
OBJECTIVES—Osteosarcoma typically occurs during puberty. Studies of the association
between height and/or birth-weight and osteosarcoma are conflicting. Therefore, we conducted a
large pooled analysis of height and birth-weight in osteosarcoma.
METHODS—Patient data from 7 studies of height, and 3 of birth-weight were obtained, resulting
in 1067 cases with height and 434 cases with birth-weight data. We compared cases to the 2000
US National Center for Health Statistics Growth Charts by simulating 1000 age and gender
matched controls per case. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for
associations between height or birth-weight and risk of osteosarcoma for each study were
estimated using logistic regression. All of the case data were combined for an aggregate analysis.
RESULTS—Compared to average birth-weight subjects (2665–4045g), individuals with high
birth-weight (≥4046g) had an increased osteosarcoma risk (OR 1.35, 95%CI 1.01–1.79). Taller
than average (51st–89th percentile) and very tall individuals (≥90th percentile) had an increased
risk of osteosarcoma (OR 1.35, 95%CI 1.18–1.54, and OR 2.60, 95%CI 2.19–3.07, respectively;
Ptrend <0.0001).
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CONCLUSIONS—This is the largest analysis of height at diagnosis and birth-weight in relation
to osteosarcoma. It suggests that rapid bone growth during puberty and in utero contributes to OS
etiology.
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INTRODUCTION
Osteosarcoma (OS) is the most common malignant bone tumor among children and
adolescents [1–3], but understanding of its etiology and risk factors is limited. Therapeutic
radiation and certain chemicals are associated with OS [4]. It also occurs more frequently in
individuals with Paget’s disease [5], and in several inherited cancer predisposition
syndromes, such as Li-Fraumeni syndrome [6], hereditary retinoblastoma [7], Diamond
Blackfan anemia [8], and Rothmund-Thomson Syndrome [9]. However, in the majority of
OS cases there is no known predisposing factor.
OS incidence has a bimodal age distribution, with a primary peak during adolescence and a
smaller, secondary peak in the elderly [10–12]. In young patients, OS occurs most
frequently at sites of rapid bone growth (e.g., the metaphyses of long bones). Its incidence is
higher in males, and the peak incidence occurs earlier in females than males, corresponding
to the pubertal growth spurt [10]. OS incidence patterns suggest that perinatal factors, as
well as growth and development may have a role in etiology [13, 14]. Evidence from
animals supports this theory in that OS is more common in large dog breeds, who have a
185-fold increased risk of OS compared with small dog breeds [15, 16]. This is consistent
with the hypothesis that rapid and/or sustained bone growth is associated with
carcinogenesis.
An association between taller stature and risk of developing OS was first suggested in 1967
[17]. Subsequently, an association with higher birth-weight has also been suggested [18]. To
date, the published data investigating the relationship between height and birth-weight and
OS risk are contradictory [17–34]. There have been several studies investigating the
relationship between height and OS, and approximately half found that OS patients are taller
than average [17, 19–25]. One study suggested an association between high birth-weight and
OS [18], but four others did not [20, 31, 33, 34]. In an attempt to better understand its
etiology, we conducted pooled and meta-analyses of height at diagnosis and birth-weight as
risk factors of OS.
METHODS
Search protocol and data collection
Birth-weight—We performed a systematic literature search of PubMed, Embase, ISI Web
of Knowledge, and MEDLINE through 2008 using combinations of the search terms
“osteosarcoma” or “bone cancer” and “birth-weight”. In addition, primary and review
articles were reviewed for reference to additional relevant studies. We identified 5 published
studies [18, 20, 31, 33, 34] that investigated the association between birth-weight and OS.
We reviewed each of these studies in detail.
Hartley et al. [33] presented only median birth-weight values for OS cases and controls.
Gelberg et al. [20] estimated ORs for birth-weight using matched and unmatched controls
with two birth-weight groupings: <2500g (referent) compared to ≥2500g; and, 1984–2977g
(referent), 2978–3313g, 3314–3664g, and 3665+g. Buckley et al. [31] estimated ORs using
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the following birth-weight groupings: 0–2700g (referent), 2800–3200g, 3200–3600g, and
3700g+. Troisi et al. [18] presented ORs with the birth-weight groupings <3000g, 3000–
3499g (referent), 3500–3999g, and 4000g+. Schüz and Forman [34] (re-analyzing a study
previously published [35]) estimated ORs for all bone cancers (not only OS) in two ways:
(1) using birth-weight by gestational age with birth-weight categories based on the
distribution of the comparison population, <10% percentile and >90% percentile for small-
and large-for-gestational age, respectively; and (2) based on low and high birth-weight
defined as <2500g and high as >4000g, compared to normal.
As one study published only median values and those that published ORs categorized birth-
weight differently and used variable referent groups, we could not use them in a meta-
analysis that combined ORs. Therefore, all of the published study groups were contacted in
an effort to collect their individual patient data. We obtained birth-weight data from the
primary investigators of 2 published studies (Troisi et al. [18] and Schüz and Forman [34])
and an unpublished case dataset from St. Jude Children’s Research Hospital. The published
studies also had control data: Troisi et al. [18] had 130 controls and Schüz and Forman [34]
had 2949 controls. This resulted in 434 OS cases with birth-weight data.
The unpublished birth-weight data from St. Jude Children’s Research Hospital included
children with newly diagnosed osteosarcoma admitted to the St. Jude Children’s Research
Hospital between February 1966 and November 2006. The sex distribution was 45.9% girls
and 54.1% boys.
Height at diagnosis—We performed a systematic literature search of PubMed, Embase,
ISI Web of Knowledge, and MEDLINE through 2008 using combinations of the search
terms “osteosarcoma” or “bone cancer” and “height” or “stature”. Additionally, primary and
review articles were reviewed for reference to additional relevant studies. We identified 16
published studies that investigated the association between height and OS.
Fourteen published studies only estimated height percentiles, mean height, and/or standard
deviation scores (SDS) [17, 19, 21–32]. Gelberg et al. [20] estimated ORs using matched
and unmatched controls for height 1 year pre-diagnosis with the following height percentile
groupings: 0–32.07% (referent), 32.08–59.63%, 59.64–86.38%, and 86.39–100%. Troisi et
al. [18] estimated ORs for height with <51st percentile (referent), 51–81, and >81st
percentile categories.
The majority of studies did not publish ORs, and one of the two that published ORs used
height 1 year prior to diagnosis. In addition, height percentiles were categorized differently.
Therefore, we could not use these studies in our meta-analysis of height at diagnosis that
combined ORs. We contacted all the published study groups in an effort to collect their
individual patient data. Most of the older studies had since destroyed their data files. We
obtained height at diagnosis data from the primary investigators of 4 published studies (Pui
et al. [29], Ruza et al. [22], Cotterill et al. [23], and Troisi et al. [18]) and 2 unpublished case
datasets from St. Jude Children’s Research Hospital and University Clinic of Navarra,
Spain. Scranton et al. [19] provided the individual data on height at diagnosis, age and
gender of 43 OS patients in their published report, so these data were also included in our
collection of published datasets. Only one study had control data of height: Troisi et al. [18]
had 139 controls with height data. We collected a total of 1067 OS cases with data on height
at diagnosis.
For the unpublished data from the University Clinic of Navarra, cases were Spanish
individuals with newly diagnosed osteosarcoma who were treated at the Department of
Pediatrics of the University Clinic of Navarra, Spain, from September 2000 to March 2009
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[described in 22]. The mean age of the patients at diagnosis was 15.6 (6.1) years and the sex
distribution was 42.2% girls and 57.8% boys. Standing height was measured with a
Harpender stadiometer (Holtain Ltd., Crymych, UK) by a trained operator.
The unpublished case data from St. Jude Children’s Research Hospital included children
under age 18 years with newly diagnosed osteosarcoma admitted to the St. Jude Children’s
Research Hospital between January 1985 and October 2007. The mean age of the patients
was 13 (3.4) years and the sex distribution was 49.5% girls and 50.5% boys.
Statistical methods
We present results for the association of birth-weight and height at diagnosis with OS based
on patient data collected from each study group analyzed individually, and combined for an
aggregate analysis, with adjusted logistic regression models.
Birth-weight—We created a reference control population that represented the distribution
of birth-weight in the general population and was comparable across studies using the 2000
U.S. National Center for Health Statistics growth standards [36]. These data were based on a
collection of 5 surveys (National Health Examination Survey II and III, National Health and
Nutrition Examination Survey I, II, and III) conducted from 1963 to 1994 [36]. For each
case, data on birth-weight for 1000 controls were generated from a normal distribution with
mean and standard deviations from the respective standard for gender for analysis of birth-
weight. This control population was combined with cases of each study [including Troisi et
al. [18] and Schüz and Forman [34] cases] and also used in an aggregate analysis.
Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence
intervals (CI) for the association between birth-weight and risk of OS for each individual
study, adjusting for gender. Race was not a confounder and thus was excluded from the
model. Low and high birth-weight values were defined based on the simulated reference
control distribution, the lowest 10% (≤2664 g) and highest 10% (≥4046 g) for low and high
birth-weight, respectively. Average birth-weight (2665–4045g) was the referent group, and
individual study cases were compared to the reference standard controls. We also analyzed
all of the data including the controls from Troisi et al. [18] and Schüz and Forman [34].
All of the individual case and reference control data were combined for an aggregated
analysis. For this analysis, logistic regression models were used to estimate ORs and 95% CI
for the association between birth-weight and risk of OS for all case data obtained compared
to the reference standard controls, adjusting for study population and gender.
Height at diagnosis—SDS were estimated for height at diagnosis, calculated as a
person’s actual height minus the mean height of the appropriate reference population for that
age and gender divided by the reference standard deviation. Reference populations were
those cited in each individual study. Unpublished data from St. Jude Children’s Research
Hospital, USA were compared to the 2000 U.S. National Center for Health Statistics Growth
Charts [36]; and unpublished data from the Department of Pediatrics, University Clinic of
Navarra, Spain were compared to the standards published for Spanish children [37]. Mean
SDSs for cases were compared to the expected value for the general population (SDS = 0)
using t-tests.
All but one study collected only case information, therefore, we created a reference control
population that represented the distribution of height in the general population and was
comparable across studies using the 2000 U.S. National Center for Health Statistics growth
standards [36]. For each case, data on height for 1000 controls were generated from a
normal distribution with mean and standard deviations from the respective standard for
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gender and age for analysis of height at diagnosis. This control population was combined
with cases of each individual study (including Troisi et al. [18] cases) and also used in an
aggregate analysis.
Logistic regression models were used to estimate ORs and 95% CI for the association
between height at diagnosis and risk of OS for each individual study, adjusting for gender
and age. Race was not a confounder and thus was excluded from the model. Height (in
centimeters) was converted to percentile of height for a person’s age and gender using 2000
U.S. National Center for Health Statistics Growth Charts [36]. Persons were defined as
“taller than average” if they were in the 51st to 89th percentile of height for their age and
gender, and they were defined as “very tall” if they were in the 90th or greater percentile of
height. “Average or below average height” (defined as ≤50th percentile of height) was used
as the referent group.
All of the individual case and reference control data were combined for an aggregated
analysis. For this analysis, logistic regression models were used to estimate ORs and 95% CI
for the association between height at diagnosis and risk of OS for all case data obtained
compared to the reference standard controls, adjusting for study population, age, and gender.
We also combined study specific ORs for height and birth-weight estimated from the studies
that provided us with individual-level data using random-effects models for a meta-analysis
[38]. Heterogeneity between studies was tested with the I2 statistic [39]. The influence of
each individual study on the overall effect was evaluated by re-computing the meta-analytic
estimates after omitting one study at a time. A funnel plot, and Begg’s and Egger’s statistical
tests were used to evaluate publication bias [40, 41]. Additional published data could not be
included in the meta-analysis due to the inconsistencies in their analysis methods (described
above).
All analyses were also performed after stratifying by gender. Statistical analyses were
carried out using SAS version 9.1 (SAS Institute, Cary, NC) and STATA version 10.1
(StataCorp, College Station, Texas) software.
RESULTS
Table 1 summarizes the 18 published studies that investigate the relationship between height
and/or birth-weight and OS [17–34]. We collected data from 6 of these studies, and
compiled a dataset of 1067 OS cases with data on height at diagnosis and 434 with data on
birth-weight (Table 2). The age range of the cases with height data was 3–64 years (mean
age = 15.6, standard deviation = 6.3; median age = 15.0). The majority of OS cases were
adolescents, 93.3% were ≤25 years of age, and only 0.4% of cases were over age 40 years
(Supplemental Figure 1 shows the age distribution by gender). As we expected, 57% of the
OS cases were male and 43% female. Of the studies with race data (Scranton et al. [19] and
Cotterill et al. [23] did not have race data; although personal communication with Cotterill et
al. [23] stated the majority were Caucasian), 79.8% of cases were White, 15.7% Black, and
4.5% Other (including all other race designations).
Birth-weight as an osteosarcoma risk factor
The average birth-weights by gender for each study are shown in Table 3, and were similar
to the 2000 U.S. National Center for Health Statistics standards (females 3290g [SD 520];
males 3410g [SD 550]) [36]. Males had a higher average birth-weight than females, with the
exception of the unpublished data collected from St. Jude Children’s Research Hospital
where males had a lower average birth-weight. Since gender had a significant effect on
birth-weight in all studies, it was adjusted for in the regression models. We found a
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significant association between increased risk of OS and high birth-weight (≥4046g),
compared to those of average birth-weight (2665–4045g), for two of the three studies, and a
marginally increased risk in an aggregated analysis (OR 1.35, 95% CI 1.01–1.79; Table 4).
Males with low birth-weight tended to have an increased risk of OS, but none of the
individual studies or aggregated analysis results were statistically significant; females with
high birth-weight had an increased risk in two of the three individual studies, and the
association was statistically significant in one study (Troisi et al. [18]: OR 1.87, 95% CI
1.00–3.51) and marginally insignificant in the aggregate analysis (Supplemental Table 1).
Individual study and aggregate ORs with and without the controls from Troisi et al. [18] and
Schüz and Forman [34] were nearly identical (data not shown).
Tall stature as an osteosarcoma risk factor
Both male and female patients with OS were significantly taller at diagnosis than the
reference population overall, and in each individual study using SDS (Table 3). Age and
gender had a significant effect on height in each study and were adjusted for in the
regression models. Five individual studies showed a statistically significant increased risk of
OS associated with very tall stature (≥90th percentile of height), and two studies suggested
an increased risk but the associations were not statistically significant (Table 5). In the
aggregated analysis we found a statistically significant increased risk of OS associated with
being taller than average (51–89th percentile of height; OR 1.35, 95% CI 1.18–1.54) and
very tall (≥90th percentile of height; OR 2.60, 95% CI 2.19–3.07) (Ptrend < 0.0001),
compared to those of average or below average height (≤50th percentile of height). Results
were similar by gender, with slightly stronger associations observed in males (aggregate
analysis, OR for ≥90th percentile of height: 2.84, 95% CI 2.28–3.53) than females
(aggregate analysis, OR for ≥90th percentile of height: 2.28, 95% CI 1.74–2.99)
(Supplemental Table 2). In an aggregated analysis restricted to 18 years of age or younger,
the associations were slightly stronger (OR for ≥90th percentile of height: 2.88, 95% CI
2.39–3.46), as well as when stratified by gender (males, OR for ≥90th percentile of height:
3.13, 95% CI 2.47–3.97; females, OR 2.50, 95% CI 1.87–3.36) (all Ptrend < 0.0001) (data
not shown).
For both height and birth-weight, ORs from the meta-analysis were very similar to the ORs
obtained from the aggregate data analysis (Supplemental Figures 2 and 3). While there was
no significant heterogeneity of individual study ORs for birth-weight, (I2, P = 0.22), there
was significant heterogeneity of individual study ORs for height (I2, P < 0.001), specifically
for the very tall subcategory (≥90th percentile of height). Stratifying by gender showed that
the height heterogeneity was only observed for males. Funnel plots (Supplemental Figure 4)
and Begg’s and Egger’s statistical tests indicated no substantial publication bias (all P
>0.05). Influence analyses additionally showed very little variation and demonstrated that no
individual study was contributing more to influence the results (data not shown).
DISCUSSION
Association studies of the relationship between stature and/or birth-weight and OS have
produced inconsistent results. However, the fact that the primary peak of OS incidence
occurs during and shortly after the pubertal growth spurt suggests that factors affecting bone
growth could contribute to OS risk. We collected height at diagnosis and birth-weight data
from six published studies and unpublished data from two centers, thus creating the largest
OS case series to date. The birth-weight analyses suggested a trend towards increased risk of
OS with high birth-weight which was significant in the aggregate analysis, particularly in
females. Our aggregate dataset of over a thousand cases strongly confirms an association
between tall stature and OS risk. A significant association between being taller than average,
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particularly for very tall individuals, and OS was consistently found in both males and
females.
Previously, high birth-weight was associated with an increased risk of OS in one study [18],
but it was not associated with OS in four others [20, 31, 33, 34]. Troisi et al. [18] published
that those with high birth-weight (≥4000g) had a significantly increased risk of OS (OR 3.9,
95% CI 1.7–10), although there was no trend in risk with increasing weight. Another large
case-control study investigating the relationship between birth-weight and OS risk found a
non-significant positive association for those with the highest birth-weight (≥3700g; OR
1.39) [31] similar to the association we observed between high birth-weight and OS (OR
1.35). The other studies [20, 33, 34] that did not observe any associations with birth-weight
may have been underpowered to detect this association. Overall, our data indicates a
marginally statistically significant association between high birth-weight and OS risk. We
did observe differences by gender; there was a statistically significant association with high
birth-weight in females, while we found no association in males. However, this finding
could also be due to chance.
High birth-weight is a risk factor for other childhood cancers, including acute lymphoblastic
leukemia (ALL) [34, 42], primary brain tumors [43], neuroblastoma [44],
rhabdomyosarcoma [45], and Wilms’ tumor [46, 47]. Interestingly, recent studies of
childhood leukemia and of Wilms’ tumor also found an increased risk only in females with
high birth-weight [47, 48]. The biological mechanism for this gender difference is unclear.
Maternal factors could affect prenatal weight gain, in particular, maternal diabetes mellitus
is known to lead to an excess of weight gain in utero and thus increased birth weight [49].
An excess of growth factors may play a role in higher birth weights; IGFs have been
suggested to play a role in fetal growth and cancer [50–52], and IGF1 has been shown to be
positively associated with birth weight [53]. Other proposed mechanisms to explain the
increased cancer risk with high birth-weight include an altered immune function [54] and
imprinting errors (loss could affect growth and have differential sex effects) [55]. High birth
weight is also associated with several adult cancers [56–58]. The latency period from
exposure to cancer development can vary significantly. It is plausible that pre-natal
exposures and a resultant high birth weight exposes the individual to additional growth
factors and, if an additional trigger is present (i.e., DNA damage or an environmental
exposure), this can lead to the development of cancer later in life.
Fraumeni [17] first suggested that the development of OS in children and adolescents was
related to tall stature and skeletal growth using epidemiologic data. Most subsequent studies
investigating the relationship between height and OS had small numbers of patients, small or
inadequate control groups, and limited statistical power. These factors could contribute to
the inconsistencies seen in the OS literature. For example, some studies found that OS
patients are not taller than average for their age and gender [18, 26–32], while others have
suggested that patients are significantly taller than average [17, 19–25]. Two recent cohort
studies with a large number of cases showed that OS patients were significantly taller at
diagnosis than the reference population [23, 24]. The case-control study by Troisi et al. [18]
found that height was not associated with OS risk; however, after examination of data from
that study we found that the control group was significantly taller than the general
population, with a SDS of 0.47, which likely contributed to the observed null association.
Gelberg et at. [20] found that those with the tallest height 1-year pre-diagnosis (defined as
86.4 to 100th percentile of height) had a significantly increased risk of OS with an OR of
2.68 (95% CI 1.14–6.30; Ptrend = 0.01), which is very similar to our finding for the tallest
individuals (≥90th percentile of height; OR 2.60). We observed significant heterogeneity
among studies of height, indicating the need for larger, high-quality studies to provide
reliable estimates of association.
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OS incidence peaks in adolescence by gender around puberty, and the age-incidence curves
closely resemble the growth velocity curves for height [59, 60]. The OS cases in our study
had very similar age and gender distributions to previously published data. The greater
incidence in males (male to female ratio of 1.34:1 in young adults) [10] and the typical
occurrence of OS in the metaphyses of lower long bones (approximately 75% in young
adults) [10] may reflect greater rates of growth [61]. The incidence peak in adolescence is
followed by a rapid decline and a plateau when bone growth is complete, after age 24 years
[62]. These incidence patterns are observed worldwide [63], and suggest that the biologic
mechanism is present during the period of growth.
Our data supporting the hypothesis that rapid bone growth contributes to OS risk in humans
are further supported by the strong positive association between OS in canines and greater
breed height [64]. Rapidly growing tissue is known to be highly susceptible to
carcinogenesis [65]. This risk could be due to rapidly proliferating osteogenic cells resulting
in increased vulnerability to oncogenic agents, development of mitotic errors, chromosome
rearrangement or neoplastic transformation [17]. OS incidence is highest during the
expected adolescent growth spurt and puberty when endogenous sex hormones, growth
hormones and IGF1 levels are at their highest, which may be involved in the pathogenesis of
OS. Insulin-like growth factors play critical roles in carcinogenesis, and genetic variation in
growth genes (e.g., insulin-like growth factor 2 receptor) have been reported to be associated
with increased risks of OS [66–68].
We assessed the correlation between birth-weight and height in the two studies with these
data from the same individuals and found a positive correlation only among males from
Troisi et al. [18]. In sensitively analyses using the Troisi et al. [18] study that mutually
adjusted for height and weight this correlation did not significantly affect our effect
estimates. A limitation of our study is the variation in OS diagnoses and birth time-periods,
and population origin. The studies with height data were conducted between 1951 and 2008,
and included individuals from the U.S., Spain, and U.K. Our findings are not likely artifacts
of changing height over time as our reference standard covers most of this time period. The
effects of country are also likely to be small since the SDS based on the standard population
referenced by each study (Table 3) and on the 2000 U.S. National Center for Health
Statistics growth standards were very similar (±0.05) for Spain and U.K. case data. Birth-
weight data were collected between 1966 and 2006, and included births in the U.S. and
Germany. The unpublished case data collected by St. Jude Children’s Research Hospital
from 1966 to 2006 covers an early time period. However, in analyses restricted to St. Jude
Children’s Research Hospital cases born 1985 or later, there was also no significant
association between high birth-weight and OS (OR 0.99, 95% CI 0.52–1.92, vs. all cases OR
1.02 95% CI 0.66–1.56).
We also compared the distributions of height and birth-weight in the published and
unpublished case series since the unpublished data were collected more recently than the
published data to evaluate if time trends may be responsible for some of the differences
observed. We found that the trend was towards higher birth-weight in the published data
(15.7% of cases) compared to the unpublished data (9.8% of cases), and for height more
unpublished cases were very tall (27.6% of cases) compared to the published case series
(21.3% of cases). If a time trend were present, the unpublished cases should have higher
birth-weights and be taller than the earlier collected case series. However, since we are
seeing the reverse trend in the birth-weight data, a time trend effect on these data is unlikely.
We also removed the unpublished case data from the pooled analyses and found that the
results were similarly significant, for being taller than average OR 1.18 (95% CI 1.0–1.4)
and very tall OR 2.27 (95% CI 1.9–2.8); and, for low and high birth-weight the ORs were
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0.82 (95% CI 0.5–1.4) and 1.78 (95% CI 1.2–2.6) without the unpublished data,
respectively.
This is the largest OS case dataset and reference population studied to date. High birth-
weight was associated with increased risk of OS in the aggregate analysis. Due to the
different results in the study sets, larger studies are needed to further investigate the
association between birth-weight and OS. We conclude that being taller than average is a
significant OS risk factor. This suggests that rapid and/or sustained bone growth during
puberty contributes to OS etiology. While our findings contribute greatly to our knowledge
of OS etiology, more work is needed to further investigate potential associations between
birth-weight and OS, and understand the physiologic mechanisms involved in predisposing
individuals with tall stature and possibly high birth-weight to OS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Studies that we obtained height at diagnosis and/or birth-weight data on osteosarcoma cases.
Author/Year Case Population
Number of cases
Ht BW
Scranton et al. 1975 [19] Children’s Hospital and Presbyterian-University Hospital of Pittsburgh, PA, USA 43 —
Pui et al. 1987 [29] St. Jude Children’s Research Hospital, TN, USA 168 —
Unpublished case data† St. Jude Children’s Research Hospital, TN, USA 214 242
Ruza et al. 2003 [22] Department of Pediatrics, University Clinic of Navarra, Spain 58 —
Unpublished case data‡ Department of Pediatrics, University Clinic of Navarra, Spain 64 —
Cotterill et al. 2004 [23] MRC Clinical Trials Unit, Cambridge and UKCCSG Data Centre, Leicester, UK 364 —
Troisi et al. 2006 [18] Orthopaedic surgery departments in 10 USA medical centers* 156 144
Schuz & Forman, 2007 [34] Nationwide GCCR, University of Mainz, Germany — 48
Total: 1067 434
Ht = height at diagnosis; BW = birth-weight; MRC = Medical Research Council; UKCCSG = United Kingdom Children’s Cancer Study Group;
*
medical centers: Massachusetts General Hospital, Boston, MA; Creighton University/St Joseph’s Hospital and University of Nebraska, Omaha,
NE; Children’s National Medical Center and Washington Hospital Center, Washington, DC; University of Chicago and Rush Presbyterian St
Luke’s, Chicago, IL; University of Florida, Gainesville, FL; University of California, Los Angeles, CA; Cleveland Clinic, Cleveland OH; GCCR =
German Childhood Cancer Registry; italics = unpublished data;
†patient height data was collected for cases diagnosed between 1985 and 2007, and birth-weight data for cases diagnosed between 1966 and 2006;
‡patient data was collected between 2001 and 2008
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Table 3
Anthropometric data by gender for each individual study and aggregate data.
Citation
Average BW (g) Ht SDS
Males (SD) Females (SD) Males (SE) Females (SE)
Scranton et al. 1975 — — 0.229 (0.22) 0.575 (0.26)*
Pui et al. 1987 — — 0.280 (0.11)* 0.235 (0.12)
Unpublished case data† 3295.5 (607.1) 3341.3 (549.3) 0.568 (0.11)** 0.331 (0.11)*
Ruza et al. 2003 — — 0.409 (0.19)* 0.639 (0.23)*
Unpublished case data‡ — — 1.17 (0.29)** 0.832 (0.16)**
Cotterill et al. 2004 — — 0.128 (0.08) 0.314 (0.11)*
Troisi et al. 2006 3462.4 (496.8) 3302.5 (549.3) 0.523 (0.15)** 0.332 (0.13)*
Schuz & Forman, 2007 3442.6 (724.9) 3383.2 (414.5) — —
Aggregate data 3368.2 (586.8) 3334.3 (532.6) 0.362 (0.05)** 0.369 (0.05)**
Ht = height at diagnosis; BW = birth-weight; SD = standard deviation; SE = standard error; SDS = standard deviation score;
†from St. Jude Children’s Research Hospital, TN, USA;
‡from University Clinic of Navarra, Spain;—, no data;
*One-sample student t-test P <0.05;
**One-sample student t-test P <0.001
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Table 4
Analysis of low and high birth-weight as osteosarcoma risk factors by individual study and aggregate data
compared to a simulated reference population.
Citation BW groups* case n (%) OR‡ (95% CI)
Troisi et al. 2006
≤2664 10 (6.9) 0.73 (0.38–1.39)
2665–4045 109 (75.7) 1 (ref)
≥4046 25 (17.4) 1.84 (1.19–2.85)
Schuz & Forman, 2007
≤2664 5 (10.4) 1.09 (0.43–2.80)
2665–4045 36 (75.0) 1 (ref)
≥4046 7 (14.6) 1.59 (0.71–3.60)
Unpublished case data†
≤2664 30 (12.4) 1.28 (0.87–1.89)
2665–4045 188 (77.7) 1 (ref)
≥4046 24 (9.9) 1.02 (0.66–1.56)
Aggregate data§
≤2664 45 (10.4) 1.08 (0.79–1.47)
2665–4045 333 (76.7) 1 (ref)
≥4046 56 (12.9) 1.35 (1.01–1.79)
*based on the birth-weight (BW) distribution in the simulated controls, low (≤2664) and high (≥4046) 10% of the control distribution;
‡
odds ratio and 95% confidence intervals, adjusted for gender;
†from St. Jude Children’s Research Hospital, TN, USA;
§
aggregate analyses were additionally adjusted for study.
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Table 5
Analysis of height at diagnosis as an osteosarcoma risk factor by individual study and aggregate data
compared to a simulated reference population.
Citation Percentile of height case n (%) OR* (95% CI)
Scranton et al. 1975
≤50th 21 (48.8) 1 (ref)
51–89th 16 (37.2) 0.94 (0.49–1.81)
≥90th 6 (14.0) 1.45 (0.59–3.60)
Pui et al. 1987
≤50th 71 (42.3) 1 (ref)
51–89th 72 (42.8) 1.25 (0.90–1.74)
≥90th 25 (14.9) 1.76 (1.12–2.78)
Unpublished case data†
≤50th 69 (32.2) 1 (ref)
51–89th 98 (45.8) 1.77 (1.30–2.41)
≥90th 47 (22.0) 3.38 (2.34–4.90)
Ruza et al. 2003
≤50th 22 (37.9) 1 (ref)
51–89th 28 (48.3) 1.56 (0.89–2.72)
≥90th 8 (13.8) 1.90 (0.85–4.28)
Unpublished case data‡
≤50th 14 (21.9) 1 (ref)
51–89th 33 (51.5) 2.82 (1.51–5.28)
≥90th 17 (26.6) 6.42 (3.16–13.03)
Cotterill et al. 2004
≤50th 150 (41.2) 1 (ref)
51–89th 146 (40.1) 1.12 (0.89–1.41)
≥90th 68 (18.7) 2.45 (1.84–3.27)
Troisi et al. 2006
≤50th 59 (37.8) 1 (ref)
51–89th 66 (42.3) 1.30 (0.91–1.84)
≥90th 31 (19.9) 2.84 (1.83–4.38)
Aggregate data§
≤50th 406 (38.2) 1 (ref)
51–89th 456 (42.9) 1.35 (1.18–1.54)
≥90th 202 (18.9) 2.60 (2.19–3.07)
*Odds ratio and 95% confidence intervals, adjusted for age and gender;
†from St. Jude Children’s Research Hospital, TN, USA;
‡from University Clinic of Navarra, Spain;
§
aggregate analyses were additionally adjusted for study.
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